Insulin costs anywhere from $25 to over $300 per vial in the United States, depending on the type, your insurance status, and whether you use a manufacturer savings program. The good news: recent price caps and discount programs mean most people can now pay $35 or less per month, though navigating the options takes some effort.
List Prices Before Discounts
The sticker price of insulin, known as the list price, is what you’d pay at a pharmacy without any insurance or savings program. For Humalog, one of the most widely used rapid-acting insulins, a single 10 mL vial (1,000 units) has a list price of $66.40. A 5-pack of Humalog KwikPens (1,500 units total) lists at $159.12.
These are Eli Lilly’s prices after a significant cut in 2023. Before that reduction, a single vial of Humalog listed for roughly $275. Other brand-name insulins from Novo Nordisk and Sanofi have followed a similar pattern of high list prices with newer discount paths layered on top. Novo Nordisk offers follow-on versions of NovoLog at 50% off the branded list price, available at any local pharmacy with a prescription.
How many vials you need per month varies widely. A person with Type 1 diabetes who uses 40 to 50 units per day would go through roughly 1.5 vials of rapid-acting insulin per month, plus additional long-acting insulin. Someone with Type 2 diabetes on a simpler regimen might need just one vial. At full list price without any program, a monthly supply can easily reach $200 to $400 or more when combining rapid-acting and long-acting insulin.
What You Pay With Medicare
If you have Medicare, your insulin costs are capped at $35 for a one-month supply of each covered insulin product, with no deductible. This applies to insulin covered under both Part B (for insulin pumps) and Part D (standard prescriptions). If you fill a three-month supply, your cost tops out at $105 total for that period. The cap applies to everyone on Medicare who takes insulin, including those receiving Extra Help (the low-income subsidy).
What You Pay With Private Insurance
Commercial insurance coverage varies more. Your out-of-pocket cost depends on your plan’s formulary, your copay tier, and your deductible. In PPO plans, the average out-of-pocket cost per insulin claim has ranged from roughly $42 to $48, though people in high-deductible plans can face significantly more before meeting their deductible.
All three major insulin manufacturers now offer copay cards for commercially insured patients. Sanofi’s copay assistance limits out-of-pocket costs to $15 or less for a 30-day supply of its diabetes medicines. Novo Nordisk offers copay savings cards bringing costs down to $25 to $35 for several insulin products. Lilly’s Insulin Value Program caps costs at $35 per month for all Lilly insulins regardless of whether you have commercial insurance.
What You Pay Without Insurance
Being uninsured used to mean paying full list price, which could easily run $300 or more per month. That’s changed substantially. Each of the three major manufacturers now has a program specifically for uninsured patients:
- Eli Lilly’s Insulin Value Program caps all Lilly insulins at $35 per month for uninsured patients.
- Sanofi’s Insulins Valyou Savings Program covers Lantus, Toujeo, Admelog, and Apidra at a flat $35 for a 30-day supply, regardless of income level.
- Novo Nordisk’s My$99Insulin provides a 30-day supply of a combination of insulin products (up to three vials or two packs of pens) for $99, which works out to about $33 per vial or $49.50 per pack of pens.
All three companies also offer patient assistance programs that provide free insulin to people who meet income-based eligibility criteria. Novo Nordisk and Sanofi both have short-term emergency supply programs as well. Novo Nordisk’s Immediate Supply program provides a free, one-time supply of up to three vials or two packs of pens for people at risk of rationing. Sanofi’s Temporary Access Program offers a one-time 30-day supply at no cost.
The Budget Option: Walmart ReliOn Insulin
Walmart sells its ReliOn brand insulin over the counter in most states for about $25 per vial. ReliOn includes NPH (intermediate-acting), Regular (short-acting), and a 70/30 mix. A box of ReliOn FlexPen costs about $44. These are human insulins rather than the newer analog insulins like Humalog or Lantus, which means they work differently in the body. Human insulin has a less predictable absorption curve and requires more careful meal timing.
ReliOn insulin serves as a lifeline for people in financial crisis, but it’s not a direct substitute for analog insulin without medical guidance. Switching insulin types changes how you dose and when you eat, and doing it without a plan increases the risk of dangerous blood sugar swings.
Why “Cheaper” Biosimilars Haven’t Always Been Cheaper
Biosimilar insulins were supposed to bring prices down through competition, similar to how generic drugs work. The reality has been more complicated. When Basaglar launched as a biosimilar alternative to Lantus with a list price 15% lower, patients didn’t necessarily save money. Research published in The American Journal of Managed Care found that Basaglar users actually spent more per claim than Lantus users across most insurance plan types, with average out-of-pocket costs of about $45.69 per claim compared to $42.29 for Lantus users in PPO plans.
The reason comes down to how insurance formularies work. Insurers negotiated lower total amounts for Basaglar (about $360 per claim versus $427 for Lantus), but passed less of that savings on to patients. Your formulary tier, copay structure, and the specific rebate deals your insurer negotiated matter more than the list price printed on the box. This is why checking your specific plan’s preferred insulin list, rather than shopping by sticker price alone, often determines what you actually pay.
How to Find Your Lowest Price
Start by identifying which insulin you’re prescribed, then work through the options in order. If you have Medicare, the $35 cap applies automatically. If you have commercial insurance, check whether your plan already has a low copay for your insulin, and if not, apply for the manufacturer’s copay card for that brand. If you’re uninsured, enroll in the manufacturer’s savings program for your prescribed insulin. Lilly and Sanofi both offer $35-per-month programs with no income requirements.
If cost is still a barrier, ask your prescriber whether you qualify for a free patient assistance program. All three major manufacturers offer these for low- and middle-income patients. The application typically requires proof of income and a prescription, and approval can take a few weeks. For urgent needs in the interim, Novo Nordisk’s and Sanofi’s emergency supply programs can bridge the gap.